



Nordic Biotech Incentive ApS

Strandvejen 125
2900 Hellerup
CVR No. 26277779

Annual report 2023

The Annual General Meeting adopted the annual report on 12.06.2024

Lars Møller Andersen
Chairman of the General Meeting

Contents

Entity details	2
Statement by Management	3
Independent auditor's report	4
Management commentary	7
Income statement for 2023	8
Balance sheet at 31.12.2023	9
Statement of changes in equity for 2023	11
Notes	12
Accounting policies	13

Entity details

Entity

Nordic Biotech Incentive ApS
Strandvejen 125
2900 Hellerup

Business Registration No.: 26277779
Registered office: Hellerup
Financial year: 01.01.2023 - 31.12.2023

Executive Board

Florian Schönharting

Auditors

Deloitte Statsautoriseret Revisionspartnerselskab
Weidekampsgade 6
2300 Copenhagen S

Statement by Management

The Executive Board has today considered and approved the annual report of Nordic Biotech Incentive ApS for the financial year 01.01.2023 - 31.12.2023.

The annual report is presented in accordance with the Danish Financial Statements Act.

In my opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2023 and of the results of its operations for the financial year 01.01.2023 - 31.12.2023.

I believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

I recommend the annual report for adoption at the Annual General Meeting.

Hellerup, 17.05.2024

Executive Board

Florian Schönharting

Independent auditor's report

To the shareholders of Nordic Biotech Incentive ApS

Opinion

We have audited the financial statements of Nordic Biotech Incentive ApS for the financial year 01.01.2023 - 31.12.2023, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2023 and of the results of its operations for the financial year 01.01.2023 - 31.12.2023 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of this auditor's report. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Entity's ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures in the notes, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Statement on the management commentary

Management is responsible for the management commentary.

Our opinion on the financial statements does not cover the management commentary, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the management commentary provides the information required by relevant law and regulations.

Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.

Copenhagen, 17.05.2024

Deloitte

Statsautoriseret Revisionspartnerselskab

CVR No. 33963556

Bill Haudal Pedersen

State Authorised Public Accountant

Identification No (MNE) mne30131

Management commentary

Primary activities

Nordic Biotech Incentive ApS was established on 28 September 2001 with the sole purpose of being a class B limited investor in Nordic Biotech K/S.

Nordic Biotech K/S is a venture capital company focusing on early stage investment, restructurings and spin-offs in the biotech industry, primarily in the Nordic area and secondarily in the rest of the EU. At present Nordic Biotech K/S has invested in Aditech Pharma AG, Forward Pharma A/S and Rose Pharma Inc.

Uncertainty relating to recognition and measurement

Nordic Biotech Incentive ApS measures the equity holding in Nordic Biotech K/S at fair value. The underlying investment in Nordic Biotech K/S is at an early stage and thereby associated with significant estimates.

Events after the balance sheet date

No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.

Income statement for 2023

	Notes	2023 DKK	2022 DKK
Gross profit/loss		133,444	(17,993)
Income from financial assets		(99,554)	(2,242,610)
Other financial income		82	0
Other financial expenses		(1,000)	(1,124)
Profit/loss before tax		32,972	(2,261,727)
Tax on profit/loss for the year		(68,494)	0
Profit/loss for the year		(35,522)	(2,261,727)
Proposed distribution of profit and loss			
Retained earnings		(35,522)	(2,261,727)
Proposed distribution of profit and loss		(35,522)	(2,261,727)

Balance sheet at 31.12.2023

Assets

	Notes	2023 DKK	2022 DKK
Other investments		1,623,755	1,723,309
Financial assets		1,623,755	1,723,309
Fixed assets		1,623,755	1,723,309
Other receivables		91,325	0
Receivables		91,325	0
Cash		12,729	11,148
Current assets		104,054	11,148
Assets		1,727,809	1,734,457

Equity and liabilities

	Notes	2023 DKK	2022 DKK
Contributed capital		300,000	300,000
Retained earnings		1,382,934	1,418,456
Equity		1,682,934	1,718,456
Other payables		44,875	16,001
Current liabilities other than provisions		44,875	16,001
Liabilities other than provisions		44,875	16,001
Equity and liabilities		1,727,809	1,734,457
Employees	1		
Fair value information	2		

Statement of changes in equity for 2023

	Contributed capital DKK	Retained earnings DKK	Total DKK
Equity beginning of year	300,000	1,418,456	1,718,456
Profit/loss for the year	0	(35,522)	(35,522)
Equity end of year	300,000	1,382,934	1,682,934

Notes

1 Employees

The Company has no employees.

The Management has not received remunerations.

2 Fair value information

	Unlisted investments DKK
Fair value end of year	1,623,755
Unrealised fair value adjustments recognised in the income statement	(99,554)

Accounting policies

Reporting class

This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of a few provisions for reporting class C.

The accounting policies applied to these financial statements are consistent with those applied last year.

Recognition and measurement

Assets are recognised in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Entity, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year.

Foreign currency translation

On initial recognition, foreign currency transactions are translated applying the exchange rate at the transaction date. Receivables, payables and other monetary items denominated in foreign currencies that have not been settled at the balance sheet date are translated using the exchange rate at the balance sheet date. Exchange differences that arise between the rate at the transaction date and the rate in effect at the payment date, or the rate at the balance sheet date, are recognised in the income statement as financial income or financial expenses.

Income statement

Gross profit or loss

Gross profit or loss comprises external expenses.

Revenue

Revenue comprises carried interest.

Other external expenses

Other external expenses include expenses relating to the Entity's ordinary activities.

Income from other fixed asset investments

Income from other fixed asset investments comprises fair value adjustment for the financial year of the Entity's investment assets which are not investments in group enterprises or associates.

Other financial income

Other financial income comprises interest income net capital or exchange gains on transactions in foreign currencies.

Other financial expenses

Other financial expenses comprise interest expenses and bank charges.

Tax on profit/loss for the year

Under Section 19 of the Danish Capital Gains Tax Act (ABL § 19), Nordic Biotech Incentive ApS has status as a tax-exempt investment company, as a result of which Danish investors are taxed on current price movements. The Company is only liable to tax on dividends received from Danish companies, which are taxed at the rate of 15%. In addition, withholding tax may arise on income originating from other countries, which is charged to profit or loss, if no recovery is possible.

Tax on profit/loss for the year

Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.

Balance sheet**Other investments**

Other investments comprise an investment in Nordic Biotech K/S, which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act § 37. Fair value are estimated on the basis of the most recent reporting from the fund, which is considered best estimate of fair value. The value adjustment are recognized in the income statement.

Receivables

Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.

Cash

Cash comprises bank deposits.

Other financial liabilities

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.